Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 26:8:778284.
doi: 10.3389/fcvm.2021.778284. eCollection 2021.

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis

Mei Qiu  1 , Li-Min Zhao  1
Affiliations
Comment

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis

Mei Qiu et al. Front Cardiovasc Med. .
No abstract available

Keywords: HFPEF; HFrEF–heart failure with reduced ejection fraction; NYHA class; SGLT2 inhibitors (gliflozins); heart failure; race; region.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Forest plots illustrating the effect of SGLT2 inhibitors on composite HF outcome in patients with HF by four important factors. (A) Effects of SGLT2 inhibitors on composite HF outcome in HF patients by Regions. (B) Effects of SGLT2 inhibitors on composite HF outcome in HF patients by Race. (C) Effects of SGLT2 inhibitors on composite HF outcome in HF patients by Baseline NYHA class. (D) Effects of SGLT2 inhibitors on composite HF outcome in HF patients by LVEF at baseline. SGLT2, sodium-glucose co-transporter-2; HF, heart failure; CI, confidence interval; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; Composite HF outcome: defined as a composite of hospitalization for HF or cardiovascular mortality.
See this image and copyright information in PMC

Comment on

References

    1. Gager GM, Gelbenegger G, Jilma B, von Lewinski D, Sourij H, Eyileten C, et al. . Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis. Front Cardiovasc Med. (2021) 8:691907. 10.3389/fcvm.2021.691907 - DOI - PMC - PubMed
    1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. . Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. (2021). 10.1056/NEJMoa2107038. [Epub ahead of print]. - DOI - PubMed
    1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. (2020) 383:1413–24. 10.1056/NEJMoa2022190 - DOI - PubMed
    1. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. . Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. (2021) 384:117–28. 10.1056/NEJMoa2030183 - DOI - PubMed
    1. McMurray J, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. . Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. (2019) 381:1995–2008. 10.1056/NEJMoa1911303 - DOI - PubMed

LinkOut - more resources